On Tuesday, Shares of Abbott Laboratories (NYSE:ABT), added 1.43% and closed at $41.17 in the last trading session. ABT stock opened its last trade at $40.85 and after floating in a range of $40.50 to $46.38. The company’s Market capitalization is $60.22 Billion with the total Outstanding Shares of 1.47 billion. During the 52-week trading session the minimum price at which share price traded, registered at $36.00 and reached to max level of $46.38. The Earnings per Share of the company stands at $1.30. Abbott (ABT) and St. Jude Medical, Inc. (STJ) declared recently a contract in principle to sell certain products to Terumo Corporation. The transaction reflects a purchase price of about $1.12 billion and is subject to the successful completion of Abbott’s acquisition of St. Jude Medical and antitrust regulatory approvals. Abbott, St. Jude Medical and Terumo are bound by the terms of an exclusivity agreement.
The divestiture is an all-cash transaction and will include the products globally for St. Jude Medical’s Angio-Seal™ and Femoseal™ vascular closure products and Abbott’s Vado® Steerable Sheath. Abbott will retain its vascular closure products, which include the Perclose ProGlide® Suture-Mediated Closure System, StarClose SE® Vascular Closure System and Prostar® XL Percutaneous Vascular Surgical System.
Following Abbott’s acquisition of St. Jude Medical, the combined business will compete in nearly every area of the cardiovascular market and hold top positions in high-growth segments, counting atrial fibrillation, structural heart and heart failure, in addition to a leading position in the high-growth neuromodulation market. This combined portfolio will have the depth, breadth and innovation to assist patients restore their health, reduce costs for payors and deliver greater value to customers.
Shares of Allergan plc Ordinary Shares (NYSE:AGN), gained 1.76% and closed at $227.94 in the last trading session. AGN stock opened its last trade at $225.34 and after floating in a range of $224.19 to $229.39. The company’s Market capitalization is $88.69 Billion with the total Outstanding Shares of 395.95 million. During the 52-week trading session the minimum price at which share price traded, registered at $224.19 and reached to max level of $229.39. The Earnings per Share of the company stands at $12.37. Allergan plc, (AGN), a leading global pharmaceutical company, declared recently that the most recent addition to the JUVÉDERM® collection of fillers, JUVÉDERM VOLBELLA® XC, is now available to physicians and patients for use in the lips for lip augmentation and for correction of perioral rhytids, commonly referred to as “lipstick lines”, in adults over the age of 21.1 In clinical trials, JUVÉDERM VOLBELLA® XC was found to effectively increase lip fullness and soften the appearance of lines around the mouth in a majority of subjects through one year.1,2* JUVÉDERM VOLBELLA® XC is the only filler proven to last through one year in both the lips and perioral rhytids with optimal treatment.2
“Our physician customers have told us perioral lines are difficult to treat and are also a top concern among patients,” said David Moatazedi, Senior Vice President US Medical Aesthetics. “We developed a soft, smooth gel appropriate for adding subtle volume to the lips and softening the appearance of perioral lines to address this specific need. We are committed to providing our doctors with products to address the evolving needs of their aesthetically-oriented patients.”
According to the American Society of Plastic Surgeons (ASPS), use of soft tissue fillers in 2015 was the fastest growing cosmetic minimally-invasive procedure.3 JUVÉDERM VOLBELLA® XC is approved specifically for the lips and perioral rhytids. JUVÉDERM VOLBELLA® XC is formulated with VYCROSS®,2 a proprietary filler technology from Allergan, which yields smooth products that have been engineered to address specific patient concerns.4 ” The most common side effects observed in clinical trials were temporary responses at the treatment site such as swelling, tenderness, bruising, firmness lumps/bumps, redness, pain, discoloration, itching and dryness. Most of these side effects resolved within 30 days.